NEW HAVEN, Conn., February 6, 2024 — Nearly one in five bone marrow transplant patients—18.5%—carry an unnecessary antibiotic allergy label, possibly complicating their care and increasing risks during a vulnerable time, according to a recent study. These labels, often based on reactions that occurred years ago, can lead doctors to prescribe less effective or more toxic alternatives.
Unnecessary Allergy Labels Complicate Care for Transplant Patients
A Yale study reveals that many patients may be needlessly avoiding crucial antibiotics, impacting treatment outcomes.
“Many antibiotic allergy labels are based on reactions that occurred years ago, often in childhood, and were never formally evaluated,†says Ami Belmont, MD, assistant professor of medicine (rheumatology, allergy and immunology) at Yale School of Medicine (YSM). “For exmaple, among patients who report a penicillin allergy, over 95% can typically tolerate penicillin.â€
Did you know? Up to 95% of people who believe they are allergic to penicillin can safely tolerate it after appropriate testing.
Why does this matter? For patients with leukemia, lymphoma, or other blood disorders undergoing bone marrow transplantation, the stakes are notably high. These individuals have severely weakened immune systems and are at increased risk of serious infection. Unnecessarily avoiding first-line antibiotics can lead to increased complications, longer hospital stays, and poorer clinical outcomes.
The Prevalence of Misleading Labels
The study, published in the Journal of Allergy and Clinical Immunology: In Practice, found that penicillin allergies were the most commonly reported.Researchers also noted that formal allergy testing was infrequently performed, and when it was, most labels were disproven. This highlights a notable gap between documented allergies and actual immune-mediated hypersensitivity.
Pro tip: If you suspect you may have outgrown an antibiotic allergy, discuss formal allergy testing with your doctor to ensure optimal treatment options.
“Formal evaluation and allergy testing allow us to clarify whether a true allergy exists and, when it doesn’t, safely remove that label,†Belmont explains. “Clarifying antibiotic allergy labels is a relatively low-risk intervention that can have meaningful downstream effects.â€
Belmont, along with her mentor E. Jennifer Edelman, MD, MHS, professor of medicine (general medicine) at YSM, and colleagues, hopes these findings will encourage clinicians to reassess antibiotic allergy labels, especially in high-risk populations.
Reader question: Should patients proactively seek allergy testing if they have a past allergy label, even without current symptoms?
“For immunocompromised patients, being able to use first-line antibiotics can make a significant difference in both short- and long-term outcomes,†Belmont concludes.
